Upstream Bio Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

UPB$3.38-5.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Collaboration revenue - related party	$607	$621	$1,757	$1,930
Operating expenses:
Research and development	15,433	7,788	41,193	20,245
General and administrative	4,067	2,219	12,010	7,469
Total operating expenses	19,500	10,007	53,203	27,714
Loss from operations	(18,893)	(9,386)	(51,446)	(25,784)
Other income (expense):
Change in fair value of preferred stock tranche right liabilities	—	4,773	2,859	14,542
Interest income	2,904	1,527	7,047	2,646
Other expense, net	(3)	(16)	(24)	(108)
Total other income, net	2,901	6,284	9,882	17,080
Net loss	$(15,992)	$(3,102)	$(41,564)	$(8,704)
Redeemable convertible preferred stock cumulative dividends	(5,041)	(3,151)	(13,041)	(14,567)
Net loss attributable to common stockholders	$(21,033)	$(6,253)	$(54,605)	$(23,271)
Net loss per share attributable to common stockholders, basic and diluted	$(6.96)	$(2.11)	$(18.15)	$(7.90)
Weighted-average common shares outstanding, basic and diluted	3,023,155	2,958,727	3,009,234	2,944,804
Comprehensive loss:
Net loss	$(15,992)	$(3,102)	$(41,564)	$(8,704)
Unrealized gain (loss) on investments, net of tax	406	(19)	330	(77)
Comprehensive loss	$(15,586)	$(3,121)	$(41,234)	$(8,781)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.